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INTRODUCTION                                                                
Thallium-201 (Tl-201) has for many years been the radiotracer of 
choice for the scintigraphic evaluation of myocardial perfusion, but 
technetium-99m (Tc-99m) methoxy-isobutylisonitrile (MIBI) was 
shown to be a reliable alternative radiopharmaceutical for detecting 
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coronary artery disease (CAD) and is preferable to Tl-201 due to the 
better physical characteristics of the Tc-99m label for imaging. The 
accuracy of the two techniques to detect CAD has also been shown to 
be equal.(1-14) Advantages of using the Tc-99m agent include better 
image quality and the ability to simultaneously assess left ventricular 
function. (5,6)
The prognostic signifi cance of a normal stress-redistribution Tl-201 
myocardial perfusion study in patients with known or suspected CAD 
is well documented, showing a benign outcome in such patients over 
the short- and long-term, with an overall cardiac event rate of less than 
1% per year.(15-31) 
Previous studies have evaluated the prognostic value of a normal 
Tc-99m MIBI stress study over a period of 6-16 months using planar 
imaging,(32) over one year using single photon emission computed 
tomography (SPECT) or planar imaging,(33) over 19.6 months using dual 
isotope Tl-201 (rest) and Tc-99m MIBI (exercise) SPECT,(34) after 
dipyridamole Tc-99m sestamibi imaging(35) and over 22 ± 13 months 
after dobutamine-atropine stress.(36) All these studies confi rmed a 
benign short-term outcome in these patients with an overall cardiac 
event rate of less than 1% per year.
Longer follow-up studies were also reported with Tc-99m MIBI and 
Tc-99m tetrofosmin.(37-40) Most of these studies reported their 
experience with all patients referred for myocardial perfusion imaging. 
However, Yang et al. specifi cally reported on 90 patients with normal 
exercise myocardial perfusion imaging studies, but with angiographic 
coronary artery disease.(41) All these reports confi rmed an overall 
cardiac event rate in patients with normal myocardial perfusion imaging 
studies of less than 1% per year.
The aim of our study was to determine whether the benign prognostic 
signifi cance of a normal Tc-99m MIBI stress-rest myocardial perfusion 
SPECT study over a longer term could also be proven in our patient 
population.
METHODS                                                                           
Patients
We performed a retrospective analysis of the outcome in 209 
consecutive patients with known or suspected CAD, reported to have 
a normal Tc-99m MIBI exercise-rest myocardial perfusion SPECT study 
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A normal Tc-99m MIBI myocardial perfusion 
study has previously been shown to indicate a benign prognosis. Our 
aim was to determine the longer term prognosis of a normal study in 
our patient population. 
Methods: A retrospective evaluation of 209 patients with a normal 
Tc-99m MIBI study was performed. Follow-up data was obtained in 
157 patients, with complete follow-up in 121 (mean follow-up period 
of 56 months). In 36 patients only partial follow-up was possible 
(32 months follow-up). No follow-up data, except for the possible 
registration of deaths, could be obtained in 52. Patients were evaluated 
for the occurrence of primary or secondary cardiac events.
Results: The study group had a moderate pre-test probability for 
coronary artery disease (48 + 30.7%). Two possible cardiac deaths 
occurred (cardiac death rate of 0.95%). No primary events occurred 
in the group with complete follow-up, but 6 secondary events were 
recorded (cardiac event rate of 4.9%). No primary or secondary 
events occurred in the partial follow-up group during the follow-up 
period. The incidence of secondary or non-fatal primary events in this 
group for the period after they were lost to follow-up or in the group 
with no follow-up could not be ascertained. There was, however, no 
statistically signifi cant difference between these groups regarding age, 
pre-test probability and exercise parameters. 
Conclusion: Similar to the fi ndings with Tl-201, our study indicates a 
favourable longer term prognosis after a normal Tc-99m MIBI study.
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performed over a three-year period. No follow-up data could be 
obtained in 52 (24.8%) of these patients. Of the remaining 157 patients, 
follow-up was complete in 121. Only partial follow-up was possible in 
36 patients, i.e. follow-up data could only be obtained for a certain 
period after the MIBI study was performed, whereafter the patients 
were lost to further follow-up.
The pre-test probability for CAD was determined by using Bayes’ 
theorem of conditional probability of age, sex and presenting 
symptom.(42) Presenting symptoms were: no symptoms, typical angina 
pectoris, and atypical (non-anginal) chest pain.(43)
Myocardial perfusion imaging
A same day exercise-rest protocol was utilised in all patients. Exercise 
was performed on a treadmill according to the Bruce protocol. An 
intravenous injection of 260 MBq (7 mCi) Tc-99m MIBI was administered 
when the patient reached the target heart rate or other accepted 
endpoint. Myocardial perfusion SPECT imaging commenced 30 min 
after injection. The rest injection of 740 MBq (20 mCi) was administered 
3 hours later and SPECT imaging performed 1 hour after injection.
SPECT data were acquired for both the exercise and rest studies, using 
a single detector rotating gamma camera equipped with a low energy 
all purpose collimator. A 20% energy window, centred around 140 keV 
was used. Thirty images were acquired into 64x64 matrix frames in the 
step-and-shoot mode at 40s per step. A 180° elliptical orbit from 45° 
right anterior oblique to 45° left posterior oblique was used.
Transaxial slices of the myocardium were reconstructed for both 
exercise and rest studies, using a Hanning fi lter with cut-off at 0,73 
cycles/cm. Horizontal and vertical long axis slices as well as short axis 
slices were subsequently generated and displayed according to the 
recommendations of the American College of Cardiology / American 
Heart Association / Society of Nuclear Medicine (ACC/AHA/SNM).(44)
Studies were reported by three experienced Nuclear Medicine 
physicians and were considered to be normal when the exercise study 
showed only homogenous distribution of the radiopharmaceutical in 
the left ventricular myocardium without any perfusion defects. Patients 
were included in the study group if the fi nal report sent to the referring 
physician was reported as being normal.
Follow-up
Follow-up data were obtained from hospital records and/or telephone 
interviews with the patients, patients’ relatives or attending general 
practitioners. In the patients where no follow-up information could be 
obtained, or where the patients were lost to follow-up (partial follow-
up), the Registrar of Deaths of the South African Department of the 
Interior was approached to obtain information regarding the number 
and cause of deaths that occurred in these patients.
Patients were evaluated for the occurrence of: 1) primary cardiac 
events (cardiac death or non-fatal myocardial infarction); 2) secondary 
cardiac events (recurrent chest pain requiring revascularisation by 
either percutaneous transluminal coronary angioplasty (PTCA) or 
coronary artery bypass grafting (CABG)); 3) no cardiac events during 
the follow-up period. Cardiac catheterisation per se was not considered 
to be a cardiac event.
Statistical analysis
Where applicable, values are presented as the mean value ± one 
standard deviation (SD) of the mean, with the range given in brackets.
Single factor analysis of variance (ANOVA) was used to test for 
signifi cant differences between the groups with complete, partial or no 
follow-up. A p-value of less than 0.05 was considered a signifi cant 
difference.
RESULTS                                                                              
Presenting features
The biographical data of the patients are summarised in Table I.
ANOVA showed no statistically signifi cant difference in mean age 
(p = 0.06) between the groups with complete, partial or no follow-up.
Forty-three of the 121 patients (36%) with complete follow-up 
presented with typical anginal chest pain, 65 (53%) had atypical chest 
pain, and 13 (11%) were asymptomatic. Of the 36 patients in whom 
only partial follow-up data were available, 14 (39%) had typical anginal 
chest pain at presentation, and 22 (61%) presented with atypical chest 
pain. In the group with no follow-up information available, 15 of the 52 
patients (29%) presented with typical anginal pain, and 32 (61%) with 
atypical chest pain. Four patients (8%) were asymptomatic and in one 
(2%) the presenting symptom was unknown. The percentage of patients 
in each group presenting with typical angina and atypical angina, and 
with no symptoms is graphically represented in Figure 1.
TABLE 1: Patient data
 Complete Partial No 
 follow-up follow-up follow-up 
Number of patients  121 36 52
Male / Female  63 / 58 15 / 21 32 / 20
Age (years) *  52.5 ± 11.2 52.1 ± 10.9 48.3 ± 9.2 
  (31 – 72) (34 – 70) (30 – 67)
Pre-test probability of CAD (%)* 48.2 ± 30.4 51.3 ± 33.9 45.2 ± 29.6
  (2.8 – 91.5) (0.8 – 91.2) (0.8 – 93.5)
Mean follow-up period (months) 55.6 ± 11.2 32.3 ± 14.6 0
  (9 – 78) (4 – 59)
Where applicable, values are presented as mean ± 1 SD followed by the range in brackets
*No statistically signifi cant difference (ANOVA) between groups
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The mean pre-test probability for CAD in our study population was 48 
± 30.7% (0.8%-94.3%). ANOVA again showed no statistically signifi cant 
difference (p = 0.65) in the mean pre-test probability between the 
group in whom follow-up was complete and the groups with partial 
follow-up or no follow-up.
Twenty-eight of the 209 patients (13.4%) (14 with complete follow-up 
information) underwent coronary angiography for their symptoms 
prior to the Tc-99m MIBI study. Of these, 11 had a normal coronary 
angiogram. Coronary artery disease was present in the remaining 17 
patients (8.1% of the study population), of whom 11 are known to have 
had a revascularisation procedure (PTCA or CABG) performed prior 
to the MIBI study. No follow-up information was available in 1 of these 
17 patients. Five of the 17 patients (2.4% of the study population) had 
signifi cant (> 50%) coronary arterial narrowing in one or more 
coronary arteries, but had no revascularisation procedure performed 
during the follow-up period, although two of these patients were lost 
to follow-up after follow-up periods of respectively 48 and 45 months. 
One of these two patients subsequently died, presumably of a myocardial 
infarction, as will be discussed later. The data of the 5 patients with 
signifi cant CAD and no revascularisation are summarised in Table 2.
Tc-99m MIBI myocardial perfusion scintigraphy
The exercise data of the study group are summarised in Table III. 
ANOVA showed no statistically signifi cant difference (p > 0.05) in any 
of the exercise parameters between the groups in which complete 
follow-up information was available and either only partial or no follow-
up information was available.
Follow-up period
The mean follow-up period for the 157 patients in whom follow-up 
data (complete or partial) could be obtained was 50.3 ± 15.5 months, 
ranging from 4 - 78 months. The mean follow-up period for the 121 
patients with complete follow-up was 55.6 ± 11.2 months (range 9 - 
78 months) and was 32.3 ± 14.6 months (range 4 - 59 months) for the 
36 patients with partial follow-up. Figure 2 shows the number of 
patients involved in each 12-month follow-up period.
FIGURE 1: Presenting symptoms of the patients in the three different follow-up categories
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TABLE 2: Patients with signifi cant CAD and no revascularisation
Patient Sex Age Follow-up period  Pre-test probability
   (months) for CAD
1* F 70 48 90.6
2 M 47 78 87.3
3 M 54 66 92.0
4 M 52 44 92.0
5 F 65 45 90.6
*Patient died 71 months after MIBI study (see text)
M = male; F = female CAD = coronary artery disease
Baseline heart rate / min 81 ± 16 80 ± 13 82 ± 13
 (43 – 126) (54 – 107) (58 – 115)
Peak heart rate / min 162 ± 13 166 ± 9 164 ± 12
 (108 – 187) (138 – 179) (122 – 178)
% of target heart rate 98 ± 5 99 ± 4 98 ± 6
 (81 – 106) (85 – 106) (74 – 100)
Baseline systolic BP (mm Hg) 138 ± 20 128 ± 15 138 ± 24
 (90 – 200) (100 – 160) (90 – 200)
Baseline diastolic BP (mm Hg) 89 ± 10 88 ± 8 91 ± 12
 (60 – 110) (70 – 100) (60 – 110)
Peak systolic BP (mm Hg) 170 ± 24 165 ± 28 176 ± 32
 (110 – 230) (120 – 210) (130 – 245)`
Peak diastolic BP (mm Hg) 90 ± 12 94 ± 11 93 ± 15
 (60 – 120) (70 – 115) (60 – 120)
TABLE 3: Tc-99m MIBI stress data
 Complete Partial No
 follow-up follow-up follow-up
BP = blood pressure
No statistically signifi cant difference (ANOVA) was found in any of the exercise parameters between groups
FIGURE 2: Number of patients involved in each 12-month follow-up period
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The main reasons for inability to obtain follow-up data were inaccurate 
hospital records (wrong telephone number and/or address), the fact 
that patients were no longer living at the available address and the 
unavailability of both an address and telephone number.
Cardiac events
Primary cardiac events:
None of the patients in whom complete follow-up information could 
be obtained, developed a cardiac death or non-fatal myocardial 
infarction during the follow-up period. Information obtained from the 
Registrar of Deaths showed that 2 patients for whom only partial or no 
follow-up information could be obtained, might have died from CAD. 
The cause of death in one patient was given as “myocardial infarction” 
on the death certifi cate. This patient died 71 months after the MIBI 
study. Follow-up information was available for the fi rst 48 months after 
the MIBI study. This patient had coronary angiography performed prior 
to the MIBI study, which showed a 70% proximal left anterior descending 
artery lesion. No revascularisation procedure was performed. A follow-
up coronary angiogram two years later failed to show any signifi cant 
coronary artery lesions. In the other patient, who died 6 weeks after 
the MIBI study, the cause of death was given as “ischemic heart disease”. 
Assuming that both these deaths were truly caused by CAD, the cardiac 
death rate in our study group was 0.95% during the whole follow-up 
period.
Secondary cardiac events:
Six of the 121 patients (4.9%) in whom follow-up was complete, had 
recurrent chest pain requiring coronary angiography followed by 
revascularisation. Of these, only 1 patient (0.8%) developed a cardiac 
event during the fi rst year after the Tc-99m MIBI study. Three cardiac 
events (2.5%) occurred during the fi rst two years and 4 (3.3%) during 
the fi rst three years. The annual cardiac event rate in this group 
was 1.1%. Table 4 summarises the relevant data of these patients. 
Revascularisation was performed at an average of 30 months 
(1 - 68 months) after the normal Tc-99m MIBI study. Only in one case 
(0.8%) was revascularisation performed less than one year after the 
MIBI study. None of the 36 patients with partial follow-up had a 
secondary cardiac event during the period for which follow-up 
information was available.
Of the 14 patients referred for the Tc-99m MIBI study after coronary 
angiography, and in whom follow-up was complete, none developed 
any coronary events during a mean follow-up period of 55 ± 11.5 
months (range 43 - 74 months), including 3 patients with signifi cant 
stenoses in one or more coronary arteries, but who did not have a 
revascularisation procedure performed. These 3 patients had a high 
mean pre-test probability for coronary artery disease (90.4 ± 2.7%) 
with a mean follow-up period of 62.7 + 17.2 months.
Fourteen patients in whom follow-up information was either incomplete 
(8) or absent (6) had coronary angiography before the MIBI study. Two 
of these had signifi cant coronary artery disease but had no 
revascularisation procedure performed. The follow-up periods were 48 
and 45 months respectively. Both had a high pre-test probability for 
CAD (90.6% each). As mentioned before, one died 71 months after 
the MIBI study.
Eleven of the 28 patients who had coronary angiography performed 
before the Tc-99m MIBI study, also had a revascularisation procedure 
(8 PTCA and 3 CABG) performed prior to the study. In 7 of these 
patients complete follow-up information could be obtained. No cardiac 
events were recorded in any of these. In 4 of the 11 patients, 
follow-up was incomplete. None of them developed any cardiac events 
during the period for which follow-up information could be obtained 
(mean = 27 ± 17.1 months). No deaths were registered for any of 
these 4 patients.
Deaths
Twelve patients (5.7%) died during the follow-up period. In seven of 
these complete follow-up information was available. Two of these 
patients died of unknown causes. The cause of death was proved to be 
of a non-cardiac origin in the remaining 5 patients. One of the patients 
in whom the cause of death could not be ascertained suffered from 
chronic bronchitis and emphysema. This patient was referred for the 
Tc-99m MIBI study because of a mildly positive effort electrocardiogram 
(ECG). This patient died 36 months after the MIBI study. The other 
patient died 61 months after the MIBI study. This patient suffered from 
chronic rheumatic heart disease with involvement of all four valves.
No follow-up information, except for the fact that the death was 
registered as well as the cause of death as given on the death certifi cate, 
was available in 5 of the 12 patients. Two of these patients presumably 
1 Atypical  Mitral valve replacement and CABG 68
 chest pain
2 Typical  PTCA 1
 chest pain
3 Typical CABG 49
 chest pain
4 Atypical CABG 15
 chest pain
5 Atypical PTCA 26
 chest pain
6 Typical CABG 23
 chest pain
TABLE 4: Patients with recurrent chest pain requiring revascularisation 
Patient Presenting Procedure Time after
 symptom  MIBI (months)
PTCA = percutaneous transluminal coronary angioplasty
CABG = coronary artery bypass grafting
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died of cardiac causes (as discussed previously). The causes of death in 
the remaining 3 patients were given as carcinoma of the pancreas, 
bronchial carcinoma and intracerebral haemorrhage.
DISCUSSION                                                                      
Myocardial perfusion scintigraphy with Tl-201 is well established as an 
excellent modality not only to diagnose CAD, but also for risk 
stratifi cation. Tc-99m-MIBI imaging is also being used for risk stratifi cation. 
Numerous studies have reported on the prognostic signifi cance of a 
normal exercise MIBI study, over a follow-up period of less than 
3 years.(32-36) These reports all confi rmed the benign outcome in patients 
with a normal MIBI study over this follow-up period. Recently published 
reports have also demonstrated a good prognosis over even longer 
follow-up periods.(37-40)
The present study was performed to investigate the outcome in 209 
patients with normal Tc-99m MIBI studies over a mean follow-up period 
of 4.2 years. In 157 patients either complete or partial follow-up 
information could be obtained. No primary cardiac events were 
recorded in 121 patients with complete follow-up, while 4.9% developed 
secondary events during the follow-up period. The annual cardiac event 
rate in this group was 1.1%. These results are comparable to those 
reported for normal Tl-201 stress imaging and the same as those 
reported for normal Tc-99m MIBI studies.
A major limitation of our study was the fact that only partial follow-up 
information was available in 36 of the 209 patients and no follow-up 
information in 52. None of the group that was partially followed for a 
mean follow-up period of 2.7 years, developed any primary or 
secondary events during the period for which follow-up information 
was available. One of these patients subsequently died of a putative 
myocardial infarction, 71 months after the MIBI study. One patient from 
the group of 52 with no follow-up information died of ischemic heart 
disease, according to the death certifi cate. From this information it is 
likely that 2 of the 209 patients might have died from a fatal primary 
cardiac event, signifying a cardiac death rate of 0.96%, confi rming the 
low cardiac death rate reported in the literature in patients with normal 
MIBI or Tl-201 studies.
It is impossible to report on the incidence of secondary cardiac events 
or non-fatal primary cardiac events in the group with no follow-up 
information or in the patients with only partial follow-up for the period 
after they were lost to follow-up. Our data, however, show that there 
was no statistically signifi cant difference between these groups and the 
group in which follow-up could be completed regarding mean age, 
treadmill exercise parameters and the pre-test probability for coronary 
artery disease. Based on these fi ndings, it could be argued that it would 
be highly unlikely that the incidence of cardiac events in these two 
groups would be signifi cantly different from that found in the group in 
which follow-up could be completed. It has been reported that patients 
with a normal exercise thallium-201 study have a benign prognosis over 
a mean 2-year follow-up period even when angiographically signifi cant 
coronary artery disease is present.(28) This was confi rmed for Tc-99m 
MIBI over a short- to medium-term follow-up period(32-34) and over a 
longer follow-up period.(37-40)
Of the 28 patients in our study group who had coronary angiography 
before the MIBI study, only 5 had signifi cant coronary artery disease, 
but no revascularisation procedures were performed. We are of the 
opinion that the small number of patients in this subset, as well as the 
subset of patients who had revascularisation performed prior to the 
MIBI study, is too small to allow any defi nitive conclusion to be drawn 
from the data.
The mean pre-test probability of coronary artery disease was moderate 
for this study group (48 + 31%), indicating the lack of a selection bias 
towards a low-risk study population and increasing the signifi cance of 
the fi nding of a low event rate amongst this group of patients with 
normal Tc-99m MIBI studies. Calculation of the pre-test probability was 
based on the prevalence of CAD in the United States.(42) The average 
age-standardised mortality rate from CAD amongst Whites, Asians and 
Coloureds in South Africa in 1989 was 291 per 100 000, compared to 
235 in the USA in 1985.(45) The mortality rate for South African Blacks 
was only 17 per 100 000. Our study population consisted mainly of 
Whites, Coloureds and Asians, with only one Black subject. It could be 
argued that the prevalence of CAD in our study group might be higher 
than in the USA, leading to the possibility that the pre-test probability 
might even be higher than that calculated using the American data.
The purpose of this study was to evaluate the longer term prognostic 
value of a normal Tc-99m MIBI SPECT myocardial perfusion study. We 
did not evaluate patients with abnormal studies and therefore cannot 
comment on the sensitivity of the test in our laboratory.
CONCLUSION                                                                    
In our study, with a mean follow-up period of 4 years, a benign outcome 
was found in 209 patients with a normal Tc-99m MIBI exercise-rest 
SPECT study, including those with angiographically proven signifi cant 
coronary artery disease or prior coronary revascularisation. Our data 
indicates that Tc-99m MIBI is comparable to Tl-201 in this respect.
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